Cambridge, Mass. – October 15, 2026 -- The U.S. Food and Drug Administration has granted a second Fast Track Designation to Marengo Therapeutics' invikafusp alfa, extending the drug's expedited status from one tumor type to all tumor mutational burden high (TMB-H) solid tumors regardless of tissue of origin.

Cambridge, Mass. – October 02, 2026 -- Marengo Therapeutics will present interim results from its STARt-002 trial combining invikafusp alfa with Gilead's TRODELVY (sacituzumab govitecan-hziy) at the Society for Immunotherapy of Cancer's 41st Annual Meeting in Phoenix, Arizona, November 4-8, 2026.

Cambridge, Mass. – September 13, 2026 -- Marengo Therapeutics has completed enrollment in the monotherapy cohorts of its Phase 1/2 STARt-001 trial evaluating invikafusp alfa across eight distinct PD-1-resistant tumor types, with updated results selected for an oral presentation at the ESMO 2026 Congress in Madrid, October 23-27.